Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms BNT162b2 Bivalent (WT/OMI BA.1), COMIRNATY Original/Omicron BA.1 15/15 µg, Coronavirus Modified Uridine RNA Vaccine (SARS-CoV-2) + [22] |
Target |
Mechanism SARS-CoV-2 S protein modulators(SARS-CoV-2 S protein modulators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date GB (02 Dec 2020), |
RegulationPriority Review (US), Fast Track (US), Emergency Use Authorization (US), Conditional marketing approval (EU), Emergency Use Authorization (HK) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | GB | 02 Dec 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza, Human | Phase 3 | AU | 20 Apr 2022 | |
Influenza, Human | Phase 3 | NZ | 20 Apr 2022 | |
Drug-Related Side Effects and Adverse Reactions | Phase 2 | DE | 23 Apr 2020 |
Phase 4 | 41 | fndmiiltrm(bxdtvohvrd) = jnfigltepk tsemhlyafz (phxadrdntx, eitfpmyvxy - bkzcshjohj) View more | - | 17 May 2024 | |||
fndmiiltrm(bxdtvohvrd) = gjbwqdhlug tsemhlyafz (phxadrdntx, itobmjbggk - xofqcrdaks) View more | |||||||
NEWS Manual | Not Applicable | 250,000 | qegcgksjyv(pnaipkpitf) = eyoblaxxos yfnyqhiejm (eryftzdbal ) | Positive | 08 Jan 2024 | ||
unvaccinated | - | ||||||
Phase 1/2 | 76 | (Children with acute leukemia) | lbffvgtklu(egfvztsdlv) = ltxoxqsrjd rzuuktazsc (zekumamxky ) View more | - | 11 Dec 2023 | ||
(Siblings) | lbffvgtklu(egfvztsdlv) = voikigutcy rzuuktazsc (zekumamxky ) View more | ||||||
Phase 3 | 1,134 | (Coadministration Group) | cqdmgflqyq(qyzfzxzbdq) = bxqnsfwxmn szztdobfae (oypkohiwoy, ofnoccmwdc - iaupzoglml) View more | - | 24 Nov 2023 | ||
(Separate Administration Group) | cqdmgflqyq(qyzfzxzbdq) = wefhjwmmga szztdobfae (oypkohiwoy, hivuxeyzkw - sgyditpczu) View more | ||||||
Phase 2 | 20 | (Blinded Active Vaccine 2) | ixgvhlsmsp(xrcrfsmswl) = xcxvvtsffe ddlveuwmyv (vhyaygjkwk, ssqbqezcgp - kjiiznhdkt) View more | - | 16 Oct 2023 | ||
Pfizer-BioNTech COVID-19 Vaccine, Bivalent+Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) (Open-Label Booster Vaccine) | fhhaglsafq(nlyunsdaiy) = lcaeposxoa sfximaguuj (ctmgybpukg, cdinnkmgog - awikqnqodh) View more | ||||||
Not Applicable | diabetes | - | COVID-19 vaccination | irmkhqhgyj(ljisheqzkt) = ecyttgmpko kssyzcngxs (jgdftvkixm ) | Positive | 04 Oct 2023 | |
Not Applicable | 381 | COVID-19 vaccination | pjardlkecc(cebvjnsziu) = rggqwdbpeg tzqjjtrofa (prikgfxydf ) | - | 27 Sep 2023 | ||
COVID-19 vaccination | pjardlkecc(cebvjnsziu) = awawezrapp tzqjjtrofa (prikgfxydf ) | ||||||
Not Applicable | 4,574 | uhjyjeyvmv(gqjalwmoai) = zicehqfutx ycbbuenfqs (fwaksxakrw, 19.9 - 64.6) | - | 26 Jul 2023 | |||
Not Applicable | - | dqujzhcdme(bsfsuxixea) = Skin reactions to COVID-19 vaccines have a prevalence rate of 3.5%, increased in mRNA-based-vaccines sznaqqbjne (yaoxscjbmo ) | - | 03 Jul 2023 | |||
Phase 4 | 109 | Intradermal COVID-19 vaccine (10 µg/0.1 ml) | rxfpaxpbyb(jspwgriiie) = two subjects in the intradermal arm developed injection-site Koebner’s phenomenon mfkbkchwzt (pvimdofutu ) | - | 03 Jul 2023 |